Maxime Beydon

ORCID: 0000-0003-4924-093X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Salivary Gland Disorders and Functions
  • Salivary Gland Tumors Diagnosis and Treatment
  • Systemic Lupus Erythematosus Research
  • Systemic Sclerosis and Related Diseases
  • Galectins and Cancer Biology
  • Diabetes and associated disorders
  • Bartonella species infections research
  • Rheumatoid Arthritis Research and Therapies
  • Fibromyalgia and Chronic Fatigue Syndrome Research
  • Climate Change and Health Impacts
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Oral Health Pathology and Treatment
  • Lymphoma Diagnosis and Treatment
  • Streptococcal Infections and Treatments
  • Atherosclerosis and Cardiovascular Diseases
  • Rabies epidemiology and control
  • Cellular transport and secretion
  • T-cell and B-cell Immunology
  • Celiac Disease Research and Management
  • Lysosomal Storage Disorders Research
  • Cytomegalovirus and herpesvirus research
  • Sports injuries and prevention
  • Parvovirus B19 Infection Studies
  • Immunodeficiency and Autoimmune Disorders
  • Statistical Methods in Clinical Trials

Assistance Publique – Hôpitaux de Paris
2021-2025

Université Paris Cité
2022-2025

Bicêtre Hospital
2020-2025

Hôpital Beaujon
2024-2025

Sorbonne Université
2024-2025

Pitié-Salpêtrière Hospital
2025

Université Paris-Saclay
2023-2024

Inserm
2024

Institut Pierre Louis d‘Épidémiologie et de Santé Publique
2023-2024

Université Paris-Est Créteil
2024

Older studies uncovered an increased risk of cancer in patients with rheumatoid arthritis between 10% and 30% compared to the general population, a lack data concerning infrequent cancers. In recent year, major therapeutic breakthroughs might have affected this by mitigating disease activity or on contrary impairing antitumoral immune response. The objectives study are compare treated all according treatment exposure.This is nationwide population-based within French national claims database...

10.1016/j.lanepe.2023.100768 article EN cc-by-nc-nd The Lancet Regional Health - Europe 2023-10-30

Objectives To estimate prevalence, incidence and mortality rates, annual healthcare costs of primary Sjögren’s syndrome (pSS) SS associated with other autoimmune disorders (SS+AID) in France. Methods French national claims-based study within the prospective Système National des Données de Santé database that includes majority population. An algorithm was developed to identify patients SS-related claims were analysed between 2011 2018. Results Overall, 23 848 pSS 14 809 SS+AID identified....

10.1136/rmdopen-2023-003591 article EN cc-by-nc RMD Open 2024-02-01

We aimed to compare disease characteristics between primary Sjögren's syndrome (pSS) patients of African ancestry (AA) and Caucasian ancestry.We conducted a retrospective, case-control study in French national European referral centre for pSS. All with pSS AA were matched two Caucasians having similar follow-up duration. explored clinical biological parameters associated cumulative EULAR Syndrome Disease Activity Index (cumESSDAI ≥5) (consisting individual clinESSDAI domain maximum...

10.1136/rmdopen-2022-002955 article EN cc-by-nc RMD Open 2023-03-01

<h3>Background</h3> The PEXIVAS (Plasma exchange and glucocorticoids in severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis) trial showed that a reduced-dose glucocorticoid regimen (redGC) was non-inferior to standard-dose (standGC) with respect death or end-stage kidney disease (ESKD) patients ANCA-associated vasculitis (AAV). However, the primary endpoint did not include progression relapse, cyclophosphamide main induction therapy rituximab (RTX)-treated tended have...

10.1136/ard-2024-226339 article EN Annals of the Rheumatic Diseases 2024-11-20

IFNα and anti-IFNα autoantibodies have been implicated in susceptibility both for systemic lupus erythematosus (SLE) viral infection. We aimed to analyze the SLE disease phenotype risk infection associated with anti-IFN-α IgG patients In this multidisciplinary retrospective single referral center study, all consecutive admitted between January 1st November 30th 2020 were considered. All subjects fulfilled ACR/EULAR 2019 criteria SLE. Anti-IFNα quantified at admission by ELISA. Demographic,...

10.1038/s41598-022-15508-9 article EN cc-by Scientific Reports 2022-07-04

A 70-year-old man reported recent swelling and erythema of both ears, sparing the lobules highly evocative relapsing polychondritis (top left image). Moreover, a fluorodeoxyglucose positron emission tomography/computed tomography (PET-CT) scan revealed ear nose cartilage hypermetabolism (bottom image), without evidence tracheobronchial involvement. Unexpectedly, cervical, mediastinal, retroperitoneal inguinal hypermetabolic lymph nodes were also detected. Serum protein electrophoresis...

10.1111/bjh.18220 article EN British Journal of Haematology 2022-05-20

<h3>Background</h3> Primary Sjögren Syndrome (pSS) patients have an increased risk of Non-Hodgkin lymphoma (NHL). There is no consensus on the therapeutic management low-grade NHL. Two strategies can be proposed; either a ''wait and see'' strategy or active strategy. <h3>Objectives</h3> To describe characteristics NHL in pSS, impact these prognosis pSS. <h3>Methods</h3> This multicentric retrospective study included all ASSESS cohort, enriched with recruited Rheumatology Internal Medicine...

10.1136/annrheumdis-2023-eular.4525 article EN Annals of the Rheumatic Diseases 2023-05-30

Background: Sjögren disease (SjD) is the autoimmune with highest lymphoma risk. Managing complicating SjD non-consensual. The aim of this study to describe characteristics, therapeutic strategies and outcome non-Hodgkin in their impact on prognosis.Methods: We conducted a multicentric retrospective including patients lymphoma. Exploratory analyses identified factors associated relapse, overall survival (OS). Using inverse probability treatment weighting, effect was compared three endpoints:...

10.2139/ssrn.4719190 preprint EN 2024-01-01

Background: Sjögren disease (SjD) is the autoimmune with highest lymphoma risk. Managing complicating SjD non-consensual. The aim of this study to describe characteristics, therapeutic strategies and outcome non-Hodgkin in their impact on prognosis. Methods: We conducted a multicentric retrospective including patients lymphoma. Exploratory analyses identified factors associated relapse, overall survival (OS). Using inverse probability treatment weighting, effect was compared three endpoints:...

10.2139/ssrn.4735621 preprint EN 2024-01-01

L'émulation d'essais cibles est un cadre méthodologique de plus en utilisé dans les études observationnelles. Cette méthode repose sur la définition du protocole l'essai randomisé cible qui aurait été mené pour répondre à question recherche, puis d'émuler au mieux chacun ses composants avec des données Dans cette revue menée échantillon d'études déclarant avoir émulé essai cible, nous avons cherché évaluer si était effectivement défini et quelle manière, examiner cohérence entre son...

10.1016/j.jeph.2024.202437 article FR Deleted Journal 2024-05-01

La maladie de Sjögren est une affection auto-immune complexe, qui persiste à poser d'importants défis malgré les progrès la recherche. Il s'agit d'une rare dont prévalence estimée entre 0.01 % et 0.05 %. Son incidence variable selon pays mais pourrait être en augmentation sur deux dernières décennies. Les facteurs risque, incluant antécédents familiaux, le stress expositions hormonales, demeurent incomplètement élucidés. peut coexister avec d'autres maladies auto-immunes particulier...

10.1016/j.rhum.2024.05.012 article FR cc-by Revue du Rhumatisme 2024-06-06

<h3>Background:</h3> Sjögren disease (SjD) is the autoimmune with highest risk of lymphoma. The most common histology marginal zone (MZ) lymphoma particularly mucosa-associated lymphoid tissue (MALT) There a continuum between autoimmunity and lymphoma, activity major factor for development. Managing complicating SjD remains non-consensual different options: wait watch, local or systemic therapy. <h3>Objectives:</h3> To describe characteristics non-Hodgkin in (SjD), therapeutic strategies,...

10.1136/annrheumdis-2024-eular.5108 article EN Annals of the Rheumatic Diseases 2024-06-01
Coming Soon ...